Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Orientbio Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is handled by 1 distinct examiner and is situated in 1 distinct art unit.
JAUHARI, SACHI is the busiest examiner, responsible for 1 pending office action. This examiner manages all of the company's current pending matters. The prosecution is entirely concentrated within 1 distinct examiner and 1 distinct art unit. This arrangement provides a consistent point of contact for the legal team.
With 1 pending office action, the portfolio shows a very low level of active prosecution. The use of 1 distinct examiner means that the company's immediate success depends on a single point of contact. Practitioners should tailor their response to the specific examination style of JAUHARI, SACHI. The involvement of 1 distinct art unit indicates a narrow technical scope for the 1 pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570031 | RELEASE-CONTROLLED TOPICAL INJECTION COMPOSITION CONTAINING CYCLIC PEPTIDE AND PREPARATION METHOD THEREFOR | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570031 | RELEASE-CONTROLLED TOPICAL INJECTION COMPOSITION CONTAINING CYCLIC PEPTIDE AND PREPARATION METHOD THEREFOR | JAUHARI, SACHI | 1654 | §103 | Non-Final OA | — | Pending | Dec 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrientbio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sachi Jauhari has the most, with 1 of Orientbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
